Advancements in Imaging-Guided Radiotherapy for Enhancing Precision and Treatment Outcomes in Patients With Solid Tumors
Article Sidebar
Main Article Content
Abstract
Background: Image-guided radiotherapy (IGRT) has evolved from planar verification and cone-beam computed tomography toward surface guidance, real-time motion management, magnetic resonance-guided radiotherapy, online adaptive planning, functional imaging, and artificial intelligence-supported workflows. Although these technologies improve geometric and dosimetric precision, uncertainty remains regarding the extent to which increasing technological complexity translates into superior long-term clinical outcomes and value across solid tumors. Objective: To narratively synthesize contemporary evidence on the role of advanced IGRT technologies in improving treatment precision, normal-tissue sparing, motion management, adaptive delivery, and clinical outcomes in patients with solid tumors, while critically evaluating limitations and implementation barriers. Methods: A narrative evidence synthesis was undertaken using 24 supplied peer-reviewed clinical studies, randomized and observational investigations, technical reports, disease-specific reviews, systematic reviews, and expert syntheses addressing conventional and emerging IGRT modalities. Evidence was organized thematically according to volumetric verification, motion management, surface guidance, MR-guided and online adaptive radiotherapy, functional imaging, and automation. Clinical outcome evidence was interpreted separately from technical and dosimetric evidence, with attention to study design, follow-up, comparator quality, patient selection, and translational limitations. Results: The most consistent evidence supported improved target localization, management of anatomical variation and motion, adaptive feasibility, and organ-at-risk sparing. MR-guided online adaptation showed particular promise for mobile or poorly visualized tumors near critical structures, although randomized comparative evidence remained limited to selected indications. Evidence for universal improvements in survival, long-term disease control, and cost-effectiveness was substantially less mature than evidence for geometric and dosimetric benefit. Conclusion: Advanced IGRT should be deployed according to clinical complexity and treatment uncertainty rather than technological availability alone. Multicenter comparative trials, standardized endpoints, longer follow-up, economic evaluation, and validated automated workflows are needed to establish where technical precision produces meaningful patient benefit
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
1. Chin S, Eccles CL, McWilliam A, Chuter R, Walker E, Whitehurst P, et al. Magnetic resonance-guided radiation therapy: a review. J Med Imaging Radiat Oncol. 2020;64(1):163-77.
2. De Crevoisier R, Lafond C, Mervoyer A, Hulot C, Jaksic N, Bessières I, et al. Image-guided radiotherapy. Cancer Radiother. 2022;26(1-2):34-49.
3. Jegal J, Park H, Kang S, Choi CH, Kim JI. Motion management and image-guided technique in photon radiation therapy: a review of an advanced technology. Prog Med Phys. 2024;35(2):21-35.
4. Al-Hallaq H, Batista V, Kügele M, Ford E, Viscariello N, Meyer J. The role of surface-guided radiation therapy for improving patient safety. Radiother Oncol. 2021;163:229-36.
5. Pakela JM, Knopf A, Dong L, Rucinski A, Zou W. Management of motion and anatomical variations in charged particle therapy: past, present, and into the future. Front Oncol. 2022;12:806153.
6. Ladbury C, Amini A, Schwer A, Liu A, Williams T, Lee P. Clinical applications of magnetic resonance-guided radiotherapy: a narrative review. Cancers (Basel). 2023;15(11):2916.
7. Bryant JM, Weygand J, Keit E, Cruz-Chamorro R, Sandoval ML, Oraiqat IM, et al. Stereotactic magnetic resonance-guided adaptive and non-adaptive radiotherapy on combination MR-linear accelerators: current practice and future directions. Cancers (Basel). 2023;15(7):2081.
8. Yoon SM, Luterstein E, Chu FI, Cao M, Lamb J, Agazaryan N, et al. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis. Cancer Med. 2021;10(17):5897-906.
9. Crockett CB, Samson P, Chuter R, Dubec M, Faivre-Finn C, Green OL, et al. Initial clinical experience of MR-guided radiotherapy for non-small cell lung cancer. Front Oncol. 2021;11:617681.
10. Courtney PT, Valle LF, Raldow AC, Steinberg ML. MRI-guided radiation therapy—an emerging and disruptive process of care: healthcare economic and policy considerations. Semin Radiat Oncol. 2024;34(1):4-13.
11. Goodburn RJ, Philippens ME, Lefebvre TL, Khalifa A, Bruijnen T, Freedman JN, et al. The future of MRI in radiation therapy: challenges and opportunities for the MR community. Magn Reson Med. 2022;88(6):2592-608.
12. Corradini S, Niyazi M, Verellen D, Valentini V, Walsh S, Grosu AL, et al. X-change symposium: status and future of modern radiation oncology—from technology to biology. Radiat Oncol. 2021;16(1):27.
13. Piruzan E, Vosoughi N, Mahdavi SR, Khalafi L, Mahani H. Target motion management in breast cancer radiation therapy. Radiol Oncol. 2021;55(4):393-408.
14. Hoegen P, Zhang KS, Tonndorf-Martini E, Weykamp F, Regnery S, Naumann P, et al. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial. Radiat Oncol. 2022;17(1):59.
15. Portelance L, Corradini S, Erickson B, Lalondrelle S, Padgett K, Van der Leij F, et al. Online magnetic resonance-guided radiotherapy (oMRgRT) for gynecological cancers. Front Oncol. 2021;11:628131.
16. Padgett KR, Simpson G, Asher D, Portelance L, Bossart E, Dogan N. Assessment of online adaptive MR-guided stereotactic body radiotherapy of liver cancers. Phys Med. 2020;77:54-63.
17. Keller B, Bruynzeel AM, Tang C, Swaminath A, Kerkmeijer L, Chu W. Adaptive magnetic resonance-guided stereotactic body radiotherapy: the next step in the treatment of renal cell carcinoma. Front Oncol. 2021;11:634830.
18. Hoegen P, Katsigiannopulos E, Buchele C, Regnery S, Weykamp F, Sandrini E, et al. Stereotactic magnetic resonance-guided online adaptive radiotherapy of adrenal metastases combines high ablative doses with optimized sparing of organs at risk. Clin Transl Radiat Oncol. 2023;39:100567.
19. Benitez CM, Steinberg ML, Cao M, Qi XS, Lamb JM, Kishan AU, et al. MRI-guided radiation therapy for prostate cancer: the next frontier in ultrahypofractionation. Cancers (Basel). 2023;15(18):4657.
20. Guerini AE, Nici S, Magrini SM, Riga S, Toraci C, Pegurri L, et al. Adoption of hybrid MRI-linac systems for the treatment of brain tumors: a systematic review of the current literature regarding clinical and technical features. Technol Cancer Res Treat. 2023;22:15330338231199286.
21. Salvestrini V, Lastrucci A, Banini M, Loi M, Carnevale MG, Olmetto E, et al. Recent advances and current challenges in stereotactic body radiotherapy for ultra-central lung tumors. Cancers (Basel). 2024;16(24):4135.
22. Chen T, Wang H. Advances in verification and delivery techniques. In: Principles and Practice of Image-Guided Abdominal Radiation Therapy. Bristol (UK): IOP Publishing; 2023. p. 17-1.
23. Renner A, Gulyas I, Buschmann M, Heilemann G, Knäusl B, Heilmann M, et al. Explicitly encoding the cyclic nature of breathing signal allows for accurate breathing motion prediction in radiotherapy with minimal training data. Phys Imaging Radiat Oncol. 2024;30:100594.
24. Guida K, Soultan D, Li H. Treatment planning for hypofractionated RT and SRS/SBRT. In: Hypofractionated and Stereotactic Radiation Therapy: A Practical Guide. Cham: Springer International Publishing; 2024. p. 79-114.